- Home
- LAB vs RIGL Comparison
LAB vs RIGL Comparison
Compare LAB & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- RIGL
- Stock Information
- Founded
- LAB 1999
- RIGL 1996
- Country
- LAB United States
- RIGL United States
- Employees
- LAB N/A
- RIGL N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- LAB Industrials
- RIGL Health Care
- Exchange
- LAB Nasdaq
- RIGL Nasdaq
- Market Cap
- LAB 562.1M
- RIGL 486.4M
- IPO Year
- LAB 2011
- RIGL 2000
- Fundamental
- Price
- LAB $2.21
- RIGL $18.45
- Analyst Decision
- LAB Strong Buy
- RIGL Buy
- Analyst Count
- LAB 2
- RIGL 5
- Target Price
- LAB $2.88
- RIGL $34.80
- AVG Volume (30 Days)
- LAB 1.6M
- RIGL 189.8K
- Earning Date
- LAB 10-30-2024
- RIGL 11-07-2024
- Dividend Yield
- LAB N/A
- RIGL N/A
- EPS Growth
- LAB N/A
- RIGL N/A
- EPS
- LAB N/A
- RIGL 0.22
- Revenue
- LAB $155,902,000.00
- RIGL $157,374,000.00
- Revenue This Year
- LAB $62.60
- RIGL $48.98
- Revenue Next Year
- LAB $9.91
- RIGL $14.43
- P/E Ratio
- LAB N/A
- RIGL $83.48
- Revenue Growth
- LAB 48.23
- RIGL 21.65
- 52 Week Low
- LAB $1.21
- RIGL $7.48
- 52 Week High
- LAB $3.04
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- LAB 65.48
- RIGL 34.16
- Support Level
- LAB $1.82
- RIGL $26.15
- Resistance Level
- LAB $2.07
- RIGL $19.80
- Average True Range (ATR)
- LAB 0.15
- RIGL 1.66
- MACD
- LAB 0.04
- RIGL -1.20
- Stochastic Oscillator
- LAB 92.45
- RIGL 0.99
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.